Suppr超能文献

O-黏蛋白降解的碳水化合物活性酶及其在炎症性肠病中的可能作用。

O-Mucin-degrading carbohydrate-active enzymes and their possible implication in inflammatory bowel diseases.

机构信息

TBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.

IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Univ Toulouse III - Paul Sabatier (UPS), Toulouse, France.

出版信息

Essays Biochem. 2023 Apr 18;67(3):331-344. doi: 10.1042/EBC20220153.

Abstract

Inflammatory bowel diseases (IBD) are modern diseases, with incidence rising around the world. They are associated with perturbation of the intestinal microbiota, and with alteration and crossing of the mucus barrier by the commensal bacteria that feed on it. In the process of mucus catabolism and invasion by gut bacteria, carbohydrate-active enzymes (CAZymes) play a critical role since mucus is mainly made up by O- and N-glycans. Moreover, the occurrence of IBD seems to be associated with low-fiber diets. Conversely, supplementation with oligosaccharides, such as human milk oligosaccharides (HMOs), which are structurally similar to intestinal mucins and could thus compete with them towards bacterial mucus-degrading CAZymes, has been suggested to prevent inflammation. In this mini-review, we will establish the current state of knowledge regarding the identification and characterization of mucus-degrading enzymes from both cultured and uncultured species of gut commensals and enteropathogens, with a particular focus on the present technological opportunities available to further the discovery of mucus-degrading CAZymes within the entire gut microbiome, by coupling microfluidics with metagenomics and culturomics. Finally, we will discuss the challenges to overcome to better assess how CAZymes targeting specific functional oligosaccharides could be involved in the modulation of the mucus-driven cross-talk between gut bacteria and their host in the context of IBD.

摘要

炎症性肠病(IBD)是现代疾病,其发病率在全球范围内呈上升趋势。它们与肠道微生物群的紊乱有关,与寄生于其上的共生菌改变和穿透黏液屏障有关。在黏液代谢和肠道细菌入侵的过程中,糖基水解酶(CAZymes)起着关键作用,因为黏液主要由 O-和 N-聚糖组成。此外,IBD 的发生似乎与低纤维饮食有关。相反,用低聚糖(如人乳寡糖(HMOs))进行补充,这些低聚糖在结构上与肠道粘蛋白相似,因此可以与它们竞争细菌降解黏液的 CAZymes,被认为可以预防炎症。在这篇迷你综述中,我们将确定和描述来自培养和未培养的肠道共生菌和肠道病原体的黏液降解酶的现有知识状态,特别关注目前可用的技术机会,通过将微流控技术与宏基因组学和培养组学相结合,进一步发现整个肠道微生物组中的黏液降解 CAZymes。最后,我们将讨论需要克服的挑战,以更好地评估靶向特定功能性寡糖的 CAZymes 如何参与 IBD 背景下肠道细菌与其宿主之间的黏液驱动的串扰调节。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8790/10154620/75f1fe8bad70/ebc-67-ebc20220153-g1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验